Form 8-K Xenon Pharmaceuticals For: Nov 12
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Xenon Pharmaceuticals (XENE) PT Raised to $56 at RBC Capital
November 13, 2024 6:48 AM ESTRBC Capital analyst Brian Abrahams raised the price target on Xenon Pharmaceuticals (NASDAQ: XENE) to $56.00 (from $55.00) while maintaining a Outperform rating.
The analyst comments "All remains on track, heading towards a big 2025 for data, with investigator MDD data 1H25 - which we believe... More
